Semax
Half-life
3 min
Time to Peak
2 min
Steady State
~1 days
Dose Range
200–1200 mcg
Frequency
Daily
Overview
Synthetic analog of the adrenocorticotropic hormone (ACTH) fragment 4-10 with added Pro-Gly-Pro C-terminal tripeptide for stability. Developed in Russia and approved there for cognitive enhancement, stroke recovery, and neuroprotection. Primarily administered intranasally. Very short half-life but extended neurological effects. Requires reconstitution for injectable use.
Mechanism of Action
Increases BDNF and NGF expression, modulates serotonergic and dopaminergic systems, and has neuroprotective properties. Enhances attention, memory, and cognitive performance.
Dosing Information
| Route | Dose Range | Half-life | Tmax | Frequency |
|---|---|---|---|---|
| Nasal | 200–1200 mcg | 3 min | 2 min | Daily, Twice daily, three times daily |
| Subcutaneous (SubQ) | 200–1200 mcg | 3 min | 2 min | Daily, Twice daily |
Storage & Handling
2-8C — Store refrigerated. Primarily used intranasally. Reconstitute with BAC water for SubQ use.
Used in Regimens
1 regimenData Sources
- Peer-reviewed Semax neuroprotective and cognitive enhancement profile
Related Tools
Track Semax with Doseline
Reminders, medication level charts, injection site rotation, and protocol tracking — all free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.